Differentiation between malignant and benign thyroid nodules and stratification of papillary thyroid cancer with aggressive histological features: Whole-lesion diffusion-weighted imaging histogram analysis

2016 ◽  
Vol 44 (6) ◽  
pp. 1546-1555 ◽  
Author(s):  
Yonghong Hao ◽  
Chu Pan ◽  
WeiWei Chen ◽  
Tao Li ◽  
WenZhen Zhu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Diffusion Weighted Imaging ◽  
Thyroid Nodules ◽  
Histogram Analysis ◽  
Papillary Thyroid ◽  
Histological Features ◽  
Diffusion Weighted ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

scholarly journals Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing

2020 ◽  
Vol 182 (1) ◽  
pp. 111-121 ◽  
Author(s):  
Daofeng Dai ◽  
Yawen Tan ◽  
Liangfeng Guo ◽  
Aifa Tang ◽  
Yongsheng Zhao
Keyword(s):  
Thyroid Cancer ◽  
Rna Sequencing ◽  
Small Rna ◽  
Thyroid Nodules ◽  
Small Rna Sequencing ◽  
Papillary Thyroid ◽  
Exosomal Mirnas ◽  
Exosomal Mirna ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

Context Exosomal miRNAs are considered potential non-invasive biomarkers for thyroid cancer. However, the global exosomal miRNAs profile for papillary thyroid cancer (PTC) has not been revealed. Objective This study investigated the diagnostic value of plasma and serum exosomal miRNAs for PTC. Methods Plasma and serum samples were collected from ten patients with benign thyroid nodules and 17 with PTC for small RNA sequencing. Plasma samples were collected from two independent cohorts, including 119 patients with PTC, 51 healthy people and 82 patients with benign thyroid nodules, for validation by quantitative reverse-transcription polymerase chain reaction (RT-qPCR). Results Small RNA sequencing identified 41 putative exosomal miRNA biomarkers for PTC. Twelve miRNAs were selected for validation. miR-376a-3p, miR-4306, miR-4433a-5p, and miR-485-3p expression significantly increased in patients with PTC compared to that in healthy people and patients with benign thyroid nodules (P ˂ 0.05). Moreover, miR-485-3p and miR-4433a-5p presented larger areas under the curve (AUCs). The high expression of exosomal miR-485-3p correlated with tumor size greater than or equal to 1 cm, advanced clinical stage, extrathyroidal extension, BRAF mutation, and lymph node metastasis. Besides, miR-485-3p exhibited the highest AUCs in diagnosing PTC patients with high-risk factors. Conclusions Plasma exosomal miR-485-3p and miR-4433a-5p might serve as biomarkers for PTC diagnosis. Plasma exosomal miR-485-3p could enable discrimination between high-risk and low-risk PTC.

Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study

2021 ◽  
Author(s):  
Taha Ulutan Kars ◽  
Mustafa Kulaksizoglu ◽  
İbrahim Kılınç
Keyword(s):  
Thyroid Cancer ◽  
Cancer Risk ◽  
Papillary Thyroid Cancer ◽  
Thyroid Nodules ◽  
Cancer Risk Assessment ◽  
Papillary Thyroid ◽  
Operating Characteristics ◽  
Discriminative Performance ◽  
Thyroid Cancer Risk ◽  
Preliminary Study

Objective: Thyroid cancer can be detected in 5–10% of patients with thyroid nodules. Management may be a challenge if fine-needle aspiration biopsy yields Bethesda III findings. Most of these cases undergo surgery and are ultimately found benign. Our aim was to evaluate whether serum osteopontin can accurately estimate thyroid cancer risk in cases with cytologically Bethesda III thyroid nodules and, thereby, decrease the number of unnecessary surgical interventions. Design and Methods: We obtained blood samples of cases with repeated cytologically Bethesda III thyroid nodules before surgery, and followed up the pathology results after thyroidectomy. We evaluated serum osteopontin from 36 patients with papillary thyroid cancer and compared them with 40 benign cases. Results: Serum osteopontin levels in patients with papillary thyroid cancer are significantly higher than in benign cases (mean serum osteopontin: 10.48 ± 3.51 ng/mL vs 6.14 ± 2.29 ng/mL, p<0.001). The area under the receiver operating characteristics curve was 0.851, suggesting that serum osteopontin could have considerable discriminative performance. Conclusions: In our preliminary study, high serum osteopontin levels can predict the risk of papillary thyroid cancer in thyroid nodules with Bethesda III cytology. Further studies are necessary to confirm these findings.

LncRNAs SNHG12 and LINC00152 were associated with progression of patients with papillary thyroid carcinoma

2019 ◽  
Vol 15 (36) ◽  
pp. 4167-4179 ◽  
Author(s):  
Jianqiu Liu ◽  
Xinyue Tang ◽  
Jing Lv ◽  
Xiaowei Peng ◽  
Ke Zhang ◽  
...  
Keyword(s):  
Gene Expression ◽  
Papillary Thyroid Carcinoma ◽  
Operating Characteristic ◽  
Thyroid Nodules ◽  
Diagnostic Value ◽  
Gene Expression Omnibus ◽  
Papillary Thyroid ◽  
Normal Tissues ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

Aim: To investigate the clinical roles of LINC00152 and SNHG12 in papillary thyroid carcinoma (PTC). Methods: LINC00152 and SNHG12 expression was sought and analysis in gene expression omnibus, The Cancer Genome Atlas and GEPIA datasets. Tumor and adjacent normal tissues were collected from 97 PTC and 44 benign thyroid nodules patients. The expression was evaluated by quantitative real-time polymerase chain reaction. The association between the expression level and clinicopathologic characteristics was analyzed by χ2 test. Receiver operating characteristic curves were plotted to evaluate the diagnostic value. Results: The expression of SNHG12 and LINC00152 were significantly higher in PTC tissues than in adjacent normal tissues not only in gene expression omnibus database but the validated samples. More interesting, LINC00152 expression level was also significantly higher in PTC tissues than that in benign thyroid nodules. The upregulation of LINC00152 and SNHG12 was associated with the malignant progression of PTC. Receiver operating characteristic curve analysis also demonstrated that there was a good trend, which indicates that they may have certain diagnostic value. Conclusion: LINC00152 and SNHG12 might serve as serve as potential related molecules of PTC.

scholarly journals Diffusion-weighted MRI in differentiating malignant from benign thyroid nodules: a meta-analysis

BMJ Open ◽  
2016 ◽  
Vol 6 (1) ◽  
pp. e008413 ◽  
Author(s):  
Lihua Chen ◽  
Jian Xu ◽  
Jing Bao ◽  
Xuequan Huang ◽  
Xiaofei Hu ◽  
...  
Keyword(s):  
Thyroid Nodules ◽  
Meta Analysis ◽  
Diffusion Weighted Mri ◽  
Diffusion Weighted ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

Quantitative Evaluation for Differentiating Malignant and Benign Thyroid Nodules Using Histogram Analysis of Grayscale Sonograms

2016 ◽  
Vol 35 (4) ◽  
pp. 775-782 ◽  
Author(s):  
Se Jin Nam ◽  
Jaeheung Yoo ◽  
Hye Sun Lee ◽  
Eun-Kyung Kim ◽  
Hee Jung Moon ◽  
...  
Keyword(s):  
Quantitative Evaluation ◽  
Thyroid Nodules ◽  
Histogram Analysis ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid

T2* mapping at 3.0T MRI for differentiation of papillary thyroid carcinoma from benign thyroid nodules

2015 ◽  
Vol 43 (4) ◽  
pp. 956-961 ◽  
Author(s):  
Ruoyang Shi ◽  
Qiuying Yao ◽  
Lianming Wu ◽  
Qinyi Zhou ◽  
Qing Lu ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Thyroid Nodules ◽  
T2 Mapping ◽  
Papillary Thyroid ◽  
3.0T Mri ◽  
Benign Thyroid Nodules ◽  
Benign Thyroid
Sign in / Sign up

Export Citation Format

Share Document